Day Two

Explore the Agenda

Pre-Conference Seminar Day

Monday, November 3

Scientific Program Day One

Tuesday, November 4

Scientific Program Day Two

Wednesday, November 5

Post-Conference Workshop Day

Thursday, November 6

7:00 am Check In, Morning Coffee & Light Refreshments

7:55 am Chair’s Opening Remarks

Jagath Reddy Junutula

President, Chief Executive Officer & Co-Founder, Aarvik Therapeutics

Spotlighting ADC Clinical & Approval Success Across 2024 & 2025 Driving ADC Access to Wider Patient Populations

8:00 am Showcasing Pivotal-Stage Clinical Performance of Sigvotatug Vedotin & PDLIV ADCs in Combination with Keytruda For First-Line Thoracic Cancers

Arati Rao

Head Vice President, Thoracic Oncology Therapeutic Area Development, Pfizer

Exploring late-stage clinical data of Sigvotatug vedotin and PDLIV ADCs in combination with Keytruda, highlighting the significance of vedotin ADCs causing immunogenic cell death vs. Topo1 ADCs
Delving into rationale and synergistic benefit of Keytruda combination approach in thoracic cancers
Laying out potential for Sigvotatug vedotin and PDLIV combinations to improve thoracic cancer standard of care and impact oncology patients

8:30 am Breaking Down ADC Manufacturing Strategy & Solutions

Lena Jonsson

Product Strategy Manager, Cytiva

Discussing tools used for the efficient and scalable manufacturing of the mAb intermediate, which serves as a key starting point for ADC conjugation
Highlighting various chromatography systems and resins used in the process, such as the ÄKTA™ systems and MabSelect PrismA™ resin, which are designed for robustness and efficient purification
Presenting the compatibility of materials in single-use systems with solvents used in the ADC manufacturing process, detailing the steps involved in the analysis

9:00 am Exploring the Clinical Profile & Journey of Datroway from TROPION-Breast Trials & Assessing Future Directions in Solid Tumor Indications

Federico Nasroulah

Executive Director, Global Clinical Lead, Oncology Clinical Development , Daiichi Sankyo

Detailing clinical data from TROPION-Breast01 trial with US and Japanese approval in previously metastatic HR positive, HER2 negative breast cancer
Exploring fresh insights from TROPION-Breast02 in triple negative breast cancer
Looking ahead to TROPION-Breast 03, 04, and 05 trials and highlighting other investigations of Datroway in solid tumors

9:30 am From IND to Long Term Commercial Supply: a Step Ahead Against the Challenges of the Bioconjugates

Giorgio Salciarini

Head of Sales, Technical Business Development, BSP Pharmaceuticals

Serving the innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
Highlights on the approach to support early stage program through robust development studies
Overview on conjugation and fill/finish capabilities
Delivering important updates on conjugation and fill-finish capacity

Discovery Chemistry Discovery Biology Preclinical Translational Medicine Clinical Lessons Process & Analytical Development Manufacturing & Supply Chain

Discovery Chemistry

Chair:

Hans-Peter Gerber

Chief Scientific Officer, Sutro Biopharma

Download the Full Event Guide for full details

Contrasting Design & Efficacy of Dual Payload ADCs Against Mono-Payload Conjugates

11:00 am Specific Dual Payload ADCs: Developing Novel β-Glucuronidase Cleavable Linker Payloads to Overcome Resistance Mechanisms

Krishna Bajjuri

Senior Director, Chemistry, Sutro Biopharma

Leveraging a cutting-edge cell-free system to develop novel dual payload ADCs
Showcasing the synergetic efficacy of Top1i combined with diverse MoA payloads to overcome the resistance
Enhancing preclinical efficacy in both in vitro and in vivo models with dual payload ADCs

11:30 am Targeting Solid Tumors & Hematological Malignancies With ADCs Utilizing Auristatin, Topo1i, & Novel Modality Payloads & Dual-Payload ADCs

Juhani Saarinen

Chief Executive Officer, Glykos

Developing a hydrophilic linker with optimized cleavable moiety to enable efficient auristatin, exatecan and novel linker-payloads for ADCs
Showing DAR4 and DAR MMAU auristatin ADCs with outstanding therapeutic window against solid tumors and hematological malignancies
Utilizing optimized linker and conjugation technologies for dual-payload ADCs

12:00 pm Exploring a Rational Design Approach to Novel Exatecan-Based Payloads for Application in Dual Conjugate ADCs

Patrick van Berkel

Chief Scientific Officer, ADC Therapeutics

Exploring the prospect of dual conjugate ADCs versus classic ADC design
Assessing generation of novel exatecan based linker-drugs to maximize the design space for dual conjugate ADCs
Examining selection of targets and payload combinations for dual conjugate ADCs

12:30 pm Session Presented by Bio-Reinnovation

12:45 pm Modeling ADC Payload Biology Using Simulated Cells

Istvan Taisz

Project Manager, Scientific, Turbine Simulated Cell Technologies

Presenting a cell signaling network-based computational model of cytotoxic payload response across diverse molecular contexts
Showcasing predicted response results from test samples across cancer subtypes, including examples with SLFN11 and SN38- Prexasertib
Demonstrating the value of cell simulations to predict drug perturbations and reveal mechanistic insights to guide ADC discovery

Discovery Biology

Chair:

James Purcell

Research Fellow, Oncology Discovery Research, Abbvie

Download the Full Event Guide for full details

Exploring ADC Targets & Antibody Engineering to De-Risk Novel Therapeutic Development

11:00 am Showcasing the Exciting Profiles of ADCs Targeting DLL3 & Evaluating Promising ADC Development Against Lower-Expressed Tumor Targets

Christian Rohlff

Chief Executive Officer & Founder, Oxford BioTherapeutics

Explaining the journey of ADC development against low-expressed tumor targets: from previously off limits to emerging advantages against modalities like TCEs
Diving into a case study of ADC development and profiles against DLL3
Exploring wider context of ADC successes and development in antigen-low populations in solid tumors

11:30 am Engineering ADCs for the Future: Integrating Target Candidate Profiles Into Design Strategies

Taruna Arora

Senior Vice President, Research, Immunome Inc.

Explaining the importance of a comprehensive set of criteria for therapeutic candidates to meet for high quality, differentiated ADCs serving unmet need
Exploring robust discovery and screening capabilities enabling ADC speed to clinic
Laying out ADC program examples leveraging target biology for differentiated Topo1 ADC development

12:00 pm Exploring Key Design & Development Attributes Contributing to Bispecific ADC Efficacy & Safety

Haiqing Hua

Senior Vice President & Head, Drug Discovery, Duality Biologics

Discussing considerations for benchmarking bispecific ADC efficacy in preclinical studies
Understanding differences in toxicity modeling for bispecific and monospecific ADCs
Looking ahead: navigating what to expect when preparing for bispecific ADC translation

12:30 pm Unlocking Intelligent Design of Bispecific & Biparatopic ADCs Using High-Throughput Single-Cell Functional Screening

Jenny Hunt (Wang)

Director - Corporate Alliances, Aureka Biotechnologies

Overviewing Aureka’s biologics discovery platform that leverages autonomous evolution, high-throughput function screening, and AI de novo design models
Co-encapsulating antibody cell library with reporter cell for high-throughput internalization functional screening
Showcasing iterative design, test, and optimize cycles to design optimal bispecific and biparatopic ADCs

Preclinical

Chair:

Zhu Chen

Senior Vice President & Head, ADC Center of Excellence, Genmab

Download the Full Event Guide for full details

Laying Out Strategy to Best Predict Translation of ADCs with Novel Targets & Formats

11:00 am Investigating the Performance of Zelenectide Pevedotin & BT5528 to Understand Class Effect Differences of Bicycle Drug Conjugates Against Traditional ADCs

Steve Walsh

Principal Scientist - Project Leader, Bicycle Therapeutics plc

Laying out preclinical and emerging clinical profiles of zelenectide pevedotin and BT5528
Making comparisons of the safety profiles of these BDCs versus traditional ADCs
Exploring opportunities for Bicycle® molecules beyond drug conjugates

11:30 am Advancing a Preclinical Pipeline of ADCs Targeting Gastrointestinal Cancers

Martin Steegmaier

Chief Scientific Officer, SOTIO Biotech a.s.

Overviewing the landscape of ADC development in colorectal and other GI cancers
Exploring discovery and preclinical development of SOT109 with potential best-in-class GI cancer-directed ADC targeting CDH17
Exploiting innovative dual-targeting ADC approaches as novel therapeutic strategy for GI and other tumors

12:00 pm Evaluating EVA1-ADC as a Novel Therapeutic Strategy for Eliminating Glioblastoma- Initiating Cells

Toru Kondo

Distinguished Professor, Institute for Genetic Medicine, University of Hokkaido

Characterizing EVA1 membrane protein as an unexplored target to eliminate Glioblastoma-Initiating Cells (GICs)
Generating high affinity anti-EVA1 antibodies to assess antibody dependent cytotoxicity and complement dependent cytotoxicity
Exploring non-clinical performance of B2E5-ADC in EVA1 expressing cell lines and GICs in culture

12:30 pm Session Presented By GENOVIS

Translational Medicine

Chair:

Gary Borzillo

Director - Clinical Sciences Oncology Translational Research, Johnson & Johnson

Download the Full Event Guide for full details

Delving Into ADC Clinical Pharmacology to Enhance Phase I Dose Escalation & Selection

11:00 am Navigating ADC Dose Finding & Selection Strategy: Challenges & Opportunities

Benjamin Wu

Director/Distinguished Scientist, Genentech

Evaluating learnings from dose selection of approved ADCs and understanding the implication to novel ADCs
Optimizing study design and dose scheduling to balance benefit-risk profiles of ADCs
Integrating quantitative modeling to guide ADC dose finding and decision

11:30 am Breaking Down Strategy & Unique Considerations to Set Up ADC Dose Escalation for Success

Cen (Cathy) Guo

Director - Clinical Pharmacology, Pfizer

Setting up first-in-patient dose escalation study for ADCs (starting dose and dose regimen selection, dose escalation increment, bioanalytical assays)
Applying modeling and simulation tools in first-inpatient study for ADCs
Selecting optimal ADC dose for expansion

12:00 pm Exploring Enhertu Dose Optimization & Selection for HER2 Mutant NSCLC Indication

Amit Khatri

Senior Director, Quantitative Clinical Pharmacology, Daiichi Sankyo

Introducing the clinical program for Enhertu in HER2-mutant NSCLC
Understanding the general principles of ADC dose selection and highlighting lessons learned from Enhertu clinical program
Breaking down the dose selection and optimization for Enhertu supporting approval in HER2 mutant NSCLC population

12:30 pm Roundtable Discussion: Understanding Challenges & Best Strategies to Optimize ADC Dose Escalation in Early Clinical Trials

What translational research can be used for ADC dose optimization?
Evaluating what quantitative methodologies are most effective for optimal dose determination
Understanding when to conduct ADC dose optimization given a typical narrow therapeutic index?
What are the pros and cons of undergoing dose optimization at different stages?

Clinical Lessons

Chair:

Gilles Gallant

Chief Development Officer, Mythic Therapeutics

Download the Full Event Guide for full details

Navigating Clinical Design & Ensuring ADC Differentiation Across Development Phases

11:00 am Analyzing the ADC Boom & Contextualizing a Growing Bioconjugate Landscape

Jake Morris

Commercial Manager, Beacon by Hanson Wade

Exploring trends and updates from preclinical and clinical ADC development
Reviewing key highlights for ADC innovation and development in 2025
Examining emerging ADC approaches including dual payloads, bispecific ADCs, and DACs
Visualizing the history of ADC development, giving perspective on how far the space has come and where it is heading

11:30 am Contextualizing Learnings From Phase I Clinical Design & Development of HDP-101

Andras Strassz

Chief Medical Officer, Heidelberg Pharma

Detailing phase I clinical data of HDP-101 targeting BCMA in multiple myeloma
Focusing on critical study design elements and challenges when developing a novel payload
Presenting study flow focusing on challenges and adaptations on clinical trial design and development strategy
Benefitting from adaptive clinical trial design by allowing flexibility in ADC dose escalation

12:00 pm Planning Late-Stage Clinical ADC Development in an Increasingly Crowded Field

Dhiraj Gambhire

Executive Director, Daiichi Sankyo

Exploring how to implement successful plan for first-in-class ADC clinical development
Outlining differences in saturated target and payload ADC landscapes – how do we demonstrate differentiation?
Explaining other late-stage considerations affecting clinical development

12:30 pm Session Presented By Halozyme

Process & Analytical Development

Chair:

Srinath Thirumalairajan

Director, Process Engineering, Pfizer

Download the Full Event Guide for full details

Tackling Development & Validation of Bioassays to Deduce ADC Activity

11:00 am Roundtable Discussion: Understanding the Opportunities & Challenges of Procedural Development & Validation of ADC Bioassays

Understanding the development journey of a bioassay program for ADC functional and procedural applications
Exploring how to make methods to be robust and repeatable for ADC bioassay validation
Assessing opportunities to adapt small molecule bioassays for ADC SAR characterization

11:30 am Session Presented By ChemExpress

12:00 pm Assessing Impact of ADC Glycan-Structure on FCGR3 Interaction & Subsequent ADCC Induction

Marieke Verweij

Senior Scientist, Functional Characterization & Bioassays, Genmab

Assessing application of qualified SPR-based FCGR-binding assays
Exploring characterization of Fc effector activity of inert and active formats
Evaluating the impact of variation of N-glycosylation structure FCGR-engagement and ADCC

12:30 pm Session Presented By Simtra

Manufacturing & Supply Chain

Chair:

Radhika Balasubramani

Director, Technical Product Steward, ADCs, Merck & Co

Download the Full Event Guide for full details

Exploring Best Practices in Scale Up & Process Characterization to De-Risk ADC CMC

11:00 am Bridging Early & Late-Stage ADC Process Development & Manufacturing Strategies

Engin Ayturk

Senior Director, CMC Bioconjugation, Process Development & Manufacturing, Exelixis, Inc.

Contrasting early versus late-stage ADC process development strategies
Laying out considerations for early vs. late-stage manufacturing challenges, priorities, and CoGs
Exploring case studies for process development and manufacturing goldilocks leveraging scale-up/down models

11:30 am Accelerating HPAPI & ADC Manufacturing Process Optimization With AI

Rohtash Kumar

Senior Vice President, Development Operations & Chief Technology Officer, Veranova

Leveraging AI to advance clinical and commercial manufacturing processes
Presenting case studies that highlight AI predictions paired with experimental validation
Introducing an innovative alternative to traditional empirical/heuristic PRD approaches

12:00 pm Understanding Manufacturing Scale Up & Supply Best Practices Under Increasingly Accelerated ADC Development Timelines

Morris Rosenberg

Chief Executive Officer, Morris Rosenberg BioPharma Consulting

Understanding approaches to scale up manufacturing fast and well as ADCs advance quicker into and through the clinic
Exploring risk mitigation strategies to counter ADC supply chain pressures
Delving into considerations and challenges with onshoring of ADC manufacturing

12:30 pm Navigating the Path to ADC Commercialization: What are the Key Questions?

Michael Trose

Senior Msat Bioconjugates Process For Capital Investment Project Specialist, Lonza

Andre Unglert

Director, Commercial Development, Bioconjugates, Lonza

Outlining considerations across scale up and BLA strategy on the path on ADC commercialization
Weighing up the use of single use or stainless-steel equipment
Assessing when you should secure capacity
What can go wrong in the progression towards ADC commercialization?

1:00 pm Lunch & Learn Presentations Hosted by Cytiva

Invitation-only session. For all other attendees, lunch is provided in the exhibition area

Discovery Chemistry Discovery Biology Preclinical Translational Medicine Clinical Lessons Process & Analytical Development Manufacturing & Supply Chain

Discovery Chemistry

Leveraging Linker Chemistry to Widen Payload Applications & Therapeutic Index

2:00 pm Leveraging Linker-Payload Chemistry to Push the Boundaries of ADC Properties & Novel Payload Strategies

Marc-Andre Kasper

Vice President Chemistry and Discovery, Tubulis GmbH

Assessing linker-payload chemistry to unlock novel ADC payload applications
Zooming in on development and performance of degrader-antibody conjugates
Breaking down lessons learned from progressing assets with linker-payload technology to the clinic

2:30 pm Contextualizing Lessons Learned & Preclinical Development of Debio 1562M & Exploring Branched Linker Technology & Design

Leo Marx

Head of ADC Research & Technologies, Debiopharm

Showcasing late preclinical development of Debio-1562M
Recapping lessons learnt with progressing high DAR ADCs from discovery to the clinic
Applying branched linker technology for novel ADCs and dual payloads applications

Discovery Biology

Novel Target Showcase: Exploring Development of ADCs Targeting Integrin Beta-6

2:00 pm Laying Out Discovery & Development of STRO-006: a Differentiated Topo1-ADC Targeting Integrin Beta-6

Helena Kiefel

Scientific Director, Sutro Biopharma

Unveiling integrin beta-6 target selection rationale alongside STRO-006 development
Exploring STRO-006 in vitro and in vivo pharmacology data and preclinical profile across CDX and PDX models
Assessing emerging ADC safety data of STRO-006

2:30 pm Showcasing Properties & Preclinical Development of ADCs Targeting Integrin Beta-6

Joe Dekker

Scientific Director, Pfizer

Exploring biology and rationale of targeting integrin beta-6
Describing early development of ADCs specifically designed to be differentiated from existing ADC therapies
Spotlighting preclinical data packages that have led to approaching first in human clinical trials

Preclinical

Spotlighting In-Depth ADC Preclinical Profiles Leading to First-in-Human Trials

2:00 pm Exploring Preclinical Characterization of IKS04 in GI Cancer & Assessing Impact of Unconjugated Antibody Co-Dosing on Tumor Penetration

Jutta Deckert

Vice President, R&D, Iksuda Therapeutics

Introducing IKS04 ultra-low DAR approach with a highly potent payload targeting CA242 in GI cancer
Explaining rationale and preclinical data for co-dosing with antibodies to improve tumor uptake of potent payload ADCs
Reviewing the preclinical profile of IKS04 and highlighting future plans for clinical investigation

2:30 pm Showcasing the INDEnabling Data of the First Click- Cleavable ADC TGW101 Targeting Non-Internalizing TAG-72

Marc robillard

cso, Tagworks Pharmaceuticals

Exploring design of TGW101 against TAG-72, cleaved in the extracellular TME by a Click-to-Release reaction
Discussing TGW101 MOA, preclinical efficacy and safety data leading to a Phase I trial
Linking TGW101 safety profile to PK and superior control of payload release, and how Click-to-Release expands ADC scope to non-internalizing targets while maximizing bystander effect

Translational Medicine

Exploring Emerging Clinical Profiles & Performance of ADCs In Oncology & Beyond

2:00 pm Showcasing Early Clinical Profile of T320 ADC Targeting TF Across Solid Tumors & Development of Novels ADC to Combat Drug Resistance

Zhican Qu

Chief Executive Officer & Founder, Nanolattix

Introducing IND-enabling preclinical profile of T320 ADC targeting TF in solid tumors
Laying out ongoing clinical trial progress of T320 ADC
Exploring future translational approach of bispecific and dual payload ADCs with design innovation to reduce drug resistance

2:30 pm Spotlighting Emerging Clinical Profiles of AOCs for Precision Therapy Applications in Muscle & Cardiac Diseases

Mike Flanagan

Chief Scientific & Technology Officer, Avidity Biosciences, Inc.

Understanding AOCs novel therapeutic approach for targeted oligonucleotide delivery to skeletal and cardiac tissues
Showcasing early clinical promise of AOCs in treating rare muscle diseases like DM1, FSHD, and DMD
Explaining AOC platform extension to precision cardiology, expanding the potential of oligonucleotide-based therapies

Clinical Lessons

Laying Out Best Practices to Streamline ADC Clinical Trial Operations & Design

2:00 pm Laying Out Regulatory Requirements & Strategies to Achieve Representative D&I in ADC Clinical Trials

Adalynn Harris

President & Chief Executive Officer, Equity Bridge

Explaining clinical trial processes and stressing the importance of regulatory requirements for clinical trial D&I
Breaking down FDORA requirements and the D&I landscape in the US to understand impact on clinical trial recruitment and study
Assessing differing strategies to achieve representative D&I across populations and locations

2:30 pm Innovation in a Continuum: Utilizing a New Model for Timely, Sustainable & Cost-Efficient ADC Clinical Development

Javad Shahidi

Senior Vice President, Biotech Unit, BeOne Medicines USA

A different era: embracing the explosion of scientific innovation in the world of ADCs
Reflecting on development and execution challenges and opportunities to improve ADC clinical trials
Laying out biotech unit experience formulating a sustainable ecosystem of scientific innovation and execution

Process & Analytical Development

Optimizing Process to Deliver ADC Quality With Novel Conjugation Technologies

2:00 pm Developing & Applying Decapping Methodology to Streamline Upstream Site-Specific Conjugation Process

Yun Yang

Senior Scientist, Merck & Co

Developing decapping methodology to assess linker payload quality and manufacturability for site-specific conjugation
Generating risk assessments to identify linker-payload candidate optimized for site-specific conjugation
Transferring process knowledge and analytical insights to clinical-stage ADC teams

2:30 pm Exploring In-Process Control Strategy for Drug-Linker Synthesis & Conjugation Process Development

Leo Ma

Associate Scientific Director - Chemistry, Manufacturing & Controls Analytical Team Lead, Bristol Myers Squibb

Leveraging multiple analytical tools to understand and define optimal conjugation process
Using analytical tools to understand and define the end of reduction, conjugation, and TFF purification process operations
Utilizing purging data of small molecule impurities during development to justify the release/stability specification of final ADC drug substance

Manufacturing & Supply Chain

Delving Into Best Practices to Develop a Robust Global ADC Regulatory CMC Strategy

2:00 pm Analyzing ADC Regulatory CMC for the FDA & Beyond: What are the Best Strategies for Global Sponsor-Regulator Interactions?

Jennifer Eck

Senior Director, CMC Regulatory Affairs, AstraZeneca

Exploring strategy for ADC global accelerated regulatory submissions
Assessing nuances between global regulatory bodies to best approach regulatory submissions and post approval changes
Understanding optimal timing and approaches to undergo health authority meetings

2:30 pm Panel Discussion: Exploring Opportunities With ADC Regulatory CMC & Making the Most of Sponsor- Regulator Interactions

Aming Zhang

Senior Director, Head of Analytical Development and QC, Pyxis Oncology

Radhika Balasubramani

Director, Technical Product Steward, ADCs, Merck & Co

Dawn Spiller

Senior Director CMC Regulatory Affairs, AstraZeneca

ADC regulatory submissions under accelerated timelines: Is it clear what is must have versus nice to have?
Comparing ADC regulatory CMC guidelines across global Health authorities
Assessing prioritizations for future industry-regulator interactions and science-based justifications for alternative control strategies

3:00 pm Afternoon Break & Networking

Putting the Why Behind ADC Clinical Profiles & Learning From the Past to Lay the Groundwork For Next Generation ADCs

4:00 pm From Cell Painting to AI Assisted CT Scans: Holistically Using Science & Medicine to Better Monitor, Prevent & Detect Interstitial Lung Disease in Solid Tumor Patients Treated with ADCs

Susan Yue

Group Medical Lead, Early Oncology Safety, Abbvie

Evaluating distinctive trends in ADC clinical trials and real-world data to characterize areas for risk mitigation
Establishing a non-clinical toolbox for comprehending pathophysiologic mechanism of action to support ADC asset design and screening
Embracing innovative, non-traditional methods to elevate risk comprehension to better select patients or decrease incidence of ILD

4:30 pm A Versatile Approach to Generating Next-Generation Antibody Conjugates Through AJICAP® Technologies

Tomohiro Fujii

ADC Researcher, Ajinomoto Bio-Pharma Services

AJICAP Conjugation: Leveraging site-specific Technologies in next-generation ADCs to enhance clinically relevant biological properties through precise DAR control such as 1, 2, 4, 8 and higher
AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and enables versatile synthesis of ADCs with higher DAR numbers, even with highly hydrophilic payloads
Application for new modality conjugates: Bispecific antibodies and AOCs produced by fully chemical conjugation technology

5:00 pm From Bench to Breakthrough: The Evolution of Amanitin ADCs – Insights from HDP-101 Phase I/II & the Future of Payload Differentiation

Andreas Pahl

CEO, Heidelberg Pharma

Differentiation through payloads: showcasing amanitin payloads and stressing the need for new ADC payload MoAs
Exploring Phase I/II dose expansion data of HDP-101 and evaluating clinical performance against conjugates with validated payloads
Reflecting on the development journey of HDP-101 to understand the hurdles to overcome with bringing a novel ADC payload to the clinic

5:30 pm Contextualizing Historical Successes & Challenges in ADCs to Set Up Future ADC Development for Success

Peter Senter

Former Distinguished Research Fellow, Independent

Deep diving into the comprehensive and chequered history of ADCs to understand how they have progressed towards standard of care oncology treatments
Translating past ADC successes and failures into 2025 and beyond: how can these lessons be applied to improve ADC design and development?
Hypothesizing future directions for the ADC field to evaluate predictions for next generation ADCs and understanding the innovation to make it a reality

6:00 pm Chair’s Closing Remarks

Jagath Reddy Junutula

President, Chief Executive Officer & Co-Founder, Aarvik Therapeutics

6:30 pm 12th Annual World ADC Awards

Nominations to open in July

8:30 pm End of Scientific Program Day Two

View Event Brochure

Pre-Conference Day

Day One

Post-Conference Workshop Day

Day Two

Explore the Agenda

7:00 am Check In, Morning Coffee & Light Refreshments

7:55 am Chair’s Opening Remarks

Spotlighting ADC Clinical & Approval Success Across 2024 & 2025 Driving ADC Access to Wider Patient Populations

8:00 am Showcasing Pivotal-Stage Clinical Performance of Sigvotatug Vedotin & PDLIV ADCs in Combination with Keytruda For First-Line Thoracic Cancers

8:30 am Breaking Down ADC Manufacturing Strategy & Solutions

9:00 am Exploring the Clinical Profile & Journey of Datroway from TROPION-Breast Trials & Assessing Future Directions in Solid Tumor Indications

9:30 am From IND to Long Term Commercial Supply: a Step Ahead Against the Challenges of the Bioconjugates

Discovery Chemistry

Chair:

Contrasting Design & Efficacy of Dual Payload ADCs Against Mono-Payload Conjugates

11:00 am Specific Dual Payload ADCs: Developing Novel β-Glucuronidase Cleavable Linker Payloads to Overcome Resistance Mechanisms

11:30 am Targeting Solid Tumors & Hematological Malignancies With ADCs Utilizing Auristatin, Topo1i, & Novel Modality Payloads & Dual-Payload ADCs

12:00 pm Exploring a Rational Design Approach to Novel Exatecan-Based Payloads for Application in Dual Conjugate ADCs

12:30 pm Session Presented by Bio-Reinnovation

12:45 pm Modeling ADC Payload Biology Using Simulated Cells

1:00 pm Lunch & Learn Presentations Hosted by Cytiva

Leveraging Linker Chemistry to Widen Payload Applications & Therapeutic Index

2:00 pm Leveraging Linker-Payload Chemistry to Push the Boundaries of ADC Properties & Novel Payload Strategies

2:30 pm Contextualizing Lessons Learned & Preclinical Development of Debio 1562M & Exploring Branched Linker Technology & Design

3:00 pm Afternoon Break & Networking

Putting the Why Behind ADC Clinical Profiles & Learning From the Past to Lay the Groundwork For Next Generation ADCs

4:00 pm From Cell Painting to AI Assisted CT Scans: Holistically Using Science & Medicine to Better Monitor, Prevent & Detect Interstitial Lung Disease in Solid Tumor Patients Treated with ADCs

4:30 pm A Versatile Approach to Generating Next-Generation Antibody Conjugates Through AJICAP® Technologies

5:00 pm From Bench to Breakthrough: The Evolution of Amanitin ADCs – Insights from HDP-101 Phase I/II & the Future of Payload Differentiation

5:30 pm Contextualizing Historical Successes & Challenges in ADCs to Set Up Future ADC Development for Success

6:00 pm Chair’s Closing Remarks

6:30 pm 12th Annual World ADC Awards

8:30 pm End of Scientific Program Day Two

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By